Literature DB >> 12583950

Serum test for assessment of patients with Bence Jones myeloma.

Arthur R Bradwell1, Hugh D Carr-Smith, Graham P Mead, Timothy C Harvey, Mark T Drayson.   

Abstract

Bence Jones protein in urine (immunoglobulin free-light-chains) is characteristic of light-chain multiple myeloma. We aimed to compare a quantitative immunoassay for serum free-light-chains with urine tests. Of 224 patients with light-chain myeloma tested at entry to clinical trials, all were correctly identified from serum samples. During monitoring of 82 patients, changes in serum and urine free-light-chains corresponded, but urine became negative for free-light-chains in 26 patients, whereas it remained abnormal in serum in 73 patients. Serum assays could replace Bence Jones protein urine tests for patients with light-chain multiple myeloma.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12583950     DOI： 10.1016/S0140-6736(03)12457-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  45 in total

1.  Using single protein biomarkers to predict health and disease in diverse patient populations: a new role for assessment of immunoglobulin free light chains.

Authors:  Mark T Drayson
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

2.  Immunoglobulin free light chains and solitary plasmacytoma of bone.

Authors:  David Dingli; Robert A Kyle; S Vincent Rajkumar; Grzegorz S Nowakowski; Dirk R Larson; John P Bida; Morie A Gertz; Terry M Therneau; L Joseph Melton; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

3.  Renal clearance of quantum dots.

Authors:  Hak Soo Choi; Wenhao Liu; Preeti Misra; Eiichi Tanaka; John P Zimmer; Binil Itty Ipe; Moungi G Bawendi; John V Frangioni
Journal:  Nat Biotechnol       Date:  2007-09-23       Impact factor: 54.908

Review 4.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

5.  Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion.

Authors:  Y Murata; K Aoe; Y Mimura-Kimura; T Murakami; K Oishi; T Matsumoto; H Ueoka; K Matsunaga; M Yano; Y Mimura
Journal:  Clin Exp Immunol       Date:  2017-07-17       Impact factor: 4.330

6.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

7.  Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients.

Authors:  Graham Peter Mead; Mark Trehane Drayson
Journal:  Blood       Date:  2009-08-20       Impact factor: 22.113

8.  Appraisal of immunoglobulin free light chain as a marker of response.

Authors:  Angela Dispenzieri; Lijun Zhang; Jerry A Katzmann; Melissa Snyder; Emily Blood; Roberta Degoey; Kimberly Henderson; Robert A Kyle; Martin M Oken; Arthur R Bradwell; Philip R Greipp
Journal:  Blood       Date:  2008-03-25       Impact factor: 22.113

9.  A clinical decision rule to aid ordering of serum and urine protein electrophoresis for case-finding of paraproteins in hospitalized inpatients.

Authors:  Ammarin Thakkinstian; Huy Tran; Glenn Reeves; Stuart Murch; John Attia
Journal:  J Gen Intern Med       Date:  2008-07-30       Impact factor: 5.128

10.  High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.

Authors:  Jochen Greiner; Anita Schmitt; Krzysztof Giannopoulos; Markus T Rojewski; Marlies Götz; Isabel Funk; Mark Ringhoffer; Donald Bunjes; Susanne Hofmann; Gerd Ritter; Hartmut Döhner; Michael Schmitt
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.